|
| Product | Company | Applications | Approval |
|
| Muromomab (Orthoclone OKT3) | Ortho Biotech, Inc. (Johnson & Johnson) | Mouse IgG2a anti-CD3. Transplantation Rejection | FDA 1986 |
| EMEA 1987 |
| Abciximab (ReoPro) | Centocor B.V. | Chimeric 7E3 directed against platelet glycoprotein IIb/IIIa | FDA 1994 |
| Nofetumomab (Verluma) | Boehringer Ingelheim Pharma KG | Mouse Fab directed against glycoprotein 40 kD (expressed in several tumours). Conjugated to Tecnecio99 | FDA 1996 |
| Imciromab-Pentetate (Myoscint) | Centocor (Johnson & Johson) | Mouse Fab-Indio111, directed against human heart miosin | FDA 1996 |
| Arcitumomab (CEA-Scan) | Immunomedics Inc. | Mouse Ig Fragment-Tecnecio99. Directed against carcinoembrionic antigen | FDA 1996 |
| EMEA 1996, |
| Retired 2005 |
| Capromab Pendetide ProstaScint | Cytogen Corp. | Mouse Ab-Indio111. Detection of prostate tumour | FDA 1996 |
| Daclizumab (Zenapax) | Hoffman-LA Roche Inc. | Humanized IgG1 anti-IL-2 . To avoid transplant rejection | FDA 1997 |
| EMEA 1999 |
| Rituximab (Rituxan) | Genentech Inc. | Chimeric Ig antiCD20 for Non-Hodgkin lymphomas | FDA 1997 |
| EMEA 1998 |
| Basiliximab (Simulect) | Novartis Phamaceutical Corp. | Chimeric anti-IL-2 (CD25). To avoid renal transplant | FDA 1998 |
| EMEA 1999 |
| Palivizaumab (Sinagis) | Medimmune Inc. | Humanized IgG1; respiratory syncitial virus | FDA 1998 |
| EMEA 1999 |
| Trastuzumab (Herceptin) | Genentech Inc. | Humanized IgG anti-HER2; breast cancer | FDA 1998 |
| EMEA 2000 |
| Remicade (Infliximab) | Centocor (Johnson & Johnson) | Chimeric anti TNF-. Rheumatoid arthritis, Crohn’s disease | FDA 1998 |
| EMEA 2002 |
| Gemtuzumab Ozogamicin (Mylotarg) | Wyeth Averst | Humanized Ig anti CD33; acute myeloid leukaemia | FDA 2000 |
| Alemtuzumab (Campath) | Millennium/ Ilex Partners LP | Humanized Ig anti CD52; chronic lymphocitic leukaemia | FDA 2001 |
| EMEA 2001 |
| Adalimumab (Humira) | Abbott Laboratories | Human anti TNF-. Rheumatoid arthritis | FDA 2002 |
| EMEA 2003 |
| Ibritumomab Tiuxetan (Zevalin) | IDEC Pharmaceuticals Corp. | Mouse Ig-Itrio 90 anti CD20. Non-Hodgkin lymphoma | FDA 2002 |
| EMEA 2004 |
| Omalizumab (Xolair) | Genentech Inc./Roche | Humanized IgE. Severe asthma | FDA 2003 |
| EMEA 2005 |
| Tositumomab (Bexxar) | GlaxoSmithKline | Murine Ig-Iodo131 anti CD20. Non-Hodgkin lymphoma | FDA 2003 |
| Efalizumab (Raptiva) | Genentech Inc./Roche | Humanized Ig anti-CD11a | FDA 2003 |
| Cetuximab (Erbitux) | ImClone Systems/ Bristol-Nyers Squibb/Merck KgaA | IgG1 directed against EGFR; colorectal tumour | FDA 2004 |
| Bevacizumab (Avastin) | Genentech Inc. | Humanized anti VEG; tumours | FDA 2004 |
| EMEA 2005 |
| Natalizumab (Tysabri) | Biogen Idec | Humanized anti CD49d. Multiple Sclerosis, Chron’s disease | FDA 2006 |
| EMEA 2006 |
| Panibizumab (Lucentis) | Genentech Inc. | Humanized anti VEGF-A. Wet Macular Degeneration | FDA 2006 |
| EMEA 2007 |
| Panimumab (Vectibix) | Amgen | Human anti EGFR (epidermal growth factor receptor). Metastatic colorectal carcinoma | FDA 2006 |
| Eculizumab (Soliris) | Alexion Pharmaceuticals Inc. | Humanized anti CD59. Paroxysmmal nocturnal hemoglobinuria | FDA 2007 |
| EMEA 2007 |
| Certolizumab Pegol (Cimzia) | UCB Pharma | Humanized Fab anti-TNF-. Morbus Chron, rheumatoid arthritis | FDA 2008 |
| Golimumab (Simponi) | Centocor (Johnson & Johnson) | Human anti TNF-. Rheumatoid psoriatic arthritis, ctiveAnkylosing spondylitis | FDA 2009 |
|
